Articles tagged with Analgesics
Researchers at SLU have identified a key molecular pathway driving cancer-related bone pain and discovered a potential solution with an existing drug. A new study provides hope for patients suffering from this debilitating condition.
Researchers found that aspirin is marginally beneficial for those who have had a previous heart attack or stroke, but offers no apparent benefit for patients with no prior history of cardiovascular issues. The study suggests that further clinical trials are needed to confirm the findings.
Researchers at UCSF found a significant association between chronic pain and faster declines in memory function and increased risk of dementia in older adults. The study suggests that chronic pain could be related to changes in the brain contributing to cognitive decline.
New research finds that older patients can tolerate more post-operative pain, despite reduced functional impairment. However, age may influence how much pain is reported due to social reasons or increased pain perception.
Researchers at Karolinska Institutet have found that a small RNA molecule in sensory neurons regulates how touch is perceived, leading to increased pain sensitivity after nerve damage. The study's results suggest that microRNA-based drugs could be a promising treatment option for chronic nerve pain.
Researchers discovered a new GPCR, substance P neurokinin 1 receptor (NK1R), that signals from the inside of neurons to sustain excitation and transmit pain. Targeting NK1R internalization alleviated pain in rats using modified compounds, offering prolonged pain relief.
Researchers have developed a new drug delivery strategy to block pain within nerve cells, offering a major breakthrough in treating chronic pain. The target protein, NK1 receptor, is controlled once it enters the cell, allowing for more effective pain suppression.
A study led by Columbia University Medical Center has shown that chronic pain may occur when pain receptors migrate from the nerve cell's surface to the cell's inner chambers. This discovery may lead to the development of a new class of medications for chronic pain that is more potent and less prone to side effects.
A recent study published in The Lancet found that ketamine does not prevent delirium and does not reduce post-surgical pain, contradicting widespread medical practices. However, higher doses of ketamine were associated with increased negative effects such as hallucinations and nightmares.
A new study published in The Lancet found that ketamine does not reduce postoperative pain or prevent delirium, but may cause hallucinations and nightmares in older patients. Researchers evaluated 672 surgery patients and found no significant effect of ketamine on postoperative pain or delirium.
Researchers discovered that a molecule called PD-L1 can mask pain by suppressing nociceptive neuron activity via PD-1. This finding could lead to the development of predictive tests and treatments for pain, as well as new ways to assess immunotherapy treatment efficacy.
The TOPIC study found that switching from a new P2Y12 inhibitor plus aspirin to maintenance DAPT with aspirin plus clopidogrel one month after acute coronary syndrome (ACS) significantly reduced bleeding risk, with a 70% lower rate of major bleeding events. Ischemic events remained similar between the two regimens.
A study by Intermountain Medical Center Heart Institute found that long-term aspirin therapy does not lower the risk of stroke for patients with atrial fibrillation who are considered low-risk for stroke. Instead, it increases the risk of gastrointestinal and genitourinary bleeding.
A recent study found a substantial correlation between increased prescriptions for pregabalin and gabapentin and rising overdose deaths. These drugs have become abuse-prone when used with heroin or other opioids, especially due to their association with feelings of loss of control and enhanced heroin effects.
The program resulted in a one-third relative reduction in postoperative complication rates and a 21 percent reduction in opioid prescribing rates. ERAS patients demonstrated significant gains, including increased early ambulation and use of early nutrition.
Researchers found that psychological interventions like relaxation and stress management reduced pain in several studies, while two dietary interventions and antibiotics also showed effects on abdominal pain. However, further research is needed due to the small and non-conclusive nature of most studies.
A study found that commonly prescribed NSAIDs increase the risk of heart attacks, with a 20-50% increased risk compared to non-users. The risk is highest with higher doses and in the first month of use.
A new guideline aims to reduce opioid use for chronic non-cancer pain by optimizing non-opioid therapy, restricting dosing, and tapering opioids. The guideline is focused on preventing harm and reducing addiction, with the goal of addressing Canada's opioid crisis.
A new Canadian clinical guideline recommends reducing opioid medication use for patients with chronic non-cancer pain, prioritizing harm reduction and optimizing non-opioid treatment. The guideline also proposes strict dose limits and trial tapers to minimize risks associated with opioids.
Researchers found that chronic sleep loss significantly exacerbates pain sensitivity in mice, but using caffeine or wakefulness-promoting agents like modafinil can block this effect. These findings suggest a new approach to chronic pain management by addressing both sleep and daytime alertness.
Researchers analyzed FDA Adverse Effect Reporting System data to find that ketamine alleviates depression symptoms in patients taking pain medication. The study also identified three other drugs with previously under-appreciated antidepressant effects: Botox, diclofenac, and minocycline.
A recent study published by City of Hope found that regular use of low-dose aspirin (81mg) reduces the risk of breast cancer in women. The study analyzed data from 57,164 participants in the California Teachers Study and found an overall 16% lower risk of breast cancer in women who took low-dose aspirin at least three times a week.
Researchers found that the p53 protein plays a key role in preventing acetaminophen-induced liver damage and promoting regeneration. Activation of p53 helps prevent injury progression while inhibition stimulates liver repair, offering hope for new treatment options.
Researchers have developed MOFs that can load and deliver ibuprofen, resulting in twice as long-lasting pain relief compared to commercial formulations. The compounds reach the bloodstream quickly and could be used for delivering other drugs orally.
Cleveland Clinic researchers found that dietary choline and TMAO levels are associated with increased blood clotting risk. Adding a low dose of aspirin may help mitigate this risk.
A new study published in Anesthesiology found that methadone significantly reduces the need for opioids after spinal fusion surgery. Patients treated with methadone required less intravenous and oral opioids to manage postoperative pain, reported lower pain scores, and had improved global satisfaction.
A review of eight studies found no link between low-dose aspirin and reduced cognitive decline. Researchers are calling for more research on the potential benefits of long-term aspirin use at younger ages.
Emergency departments are increasingly using intranasal medication administration as an alternative to injections or IVs, offering a fast and noninvasive route to deliver medications directly to the brain. This method requires no needles, is less painful than IVs or injections, and minimizes infectious disease spread.
Researchers analyzed 11 trials involving 6,560 PVD patients and found no significant effect on death rates or major cardiac events. The study suggests that aspirin therapy may not be beneficial for certain patients with peripheral vascular disease.
A new study finds that patients with certain pre-operative conditions, such as smoking or depression, are more likely to become long-term opioid users after surgery. The research suggests that other factors contribute to the risk of prolonged opioid use beyond the normal recovery period.
Researchers discovered new structural details of an angiotensin II receptor called AT2, which could be a target for new medicines. The information uncovered could give drug developers a new path for compounds that combat pain and inflammation or promote tissue regeneration.
Scientists discovered that nerve cells in ganglia can exchange information and modify sensory input to the central nervous system. This finding has potential implications for developing non-addictive painkillers targeting the peripheral nervous system.
A new study by ER docs shows that administering medications via the nose can be a helpful option for certain patients, especially children. Intranasal administration of midazolam, fentanyl, naloxone, ketamine, and dexmedetomidine can provide effective pain relief and seizure treatment.
Patients with good provider communication are more likely to use prescribed cholesterol-lowering statin drugs, take aspirin, and comply with treatment plans. They also experience better health outcomes and lower healthcare expenditures compared to those with poor communication.
Researchers discovered a novel therapeutic target called LPCAT2 that could effectively treat neuropathic pain. The study also identified a platelet alleviating factor (PAF) pain loop that affects neuropathic pain, suggesting potential benefits from PAF-receptor antagonists.
A new analysis found that apixaban, a non-vitamin K antagonist oral anticoagulant (NOAC), is superior to warfarin in reducing brain bleeds and stroke risk in patients with atrial fibrillation. The study showed that apixaban reduced intracranial hemorrhage by 58% compared to warfarin.
The American College of Physicians (ACP) issues recommendations for preventing and treating substance use disorders involving illicit and prescription drugs. Key findings include limited access to care, with only 18% of those needing treatment receiving it, and the need for expanded public health initiatives and improved prescribing pr...
The American College of Physicians recommends treating substance use disorders as chronic medical conditions with evidence-based public and individual health initiatives. The guidelines aim to improve access to care and reduce the societal burden of these disorders.
A systematic review found moderate evidence that duloxetine and venlaxine were effective in reducing neuropathy-related pain, while pregabalin and oxcarbazepine showed weak evidence. However, gabapentin was not more effective than placebo.
A new study recommends that pharmacies offer naloxone universally to patients taking opioid medications, without a prescription requirement. This could lead to a significant decrease in opioid-related overdose deaths.
A new study from The George Institute found that pregabalin treatment did not relieve pain but caused side effects like dizziness. Despite this, many patients reported being satisfied with the treatment, highlighting the need for alternative management options for sciatica.
A Phase 2 study found that replacing aspirin with low-dose rivaroxaban in addition to an antiplatelet medication does not increase bleeding complications in patients with acute coronary syndrome. The study, which involved over 3,000 patients, suggests that this dual therapy approach may be a safe alternative to lifelong aspirin treatment.
A low-dose blood-thinning medication reduced VTE recurrences more than threefold compared to aspirin without increasing bleeding side effects, according to a large international study. The study's findings support the use of rivaroxaban as a safe and effective treatment option for patients at risk for recurrent VTE.
A large international study found that rivaroxaban is more effective and safer than aspirin at preventing recurrent blood clots. The study showed that patients taking rivaroxaban had significantly lower rates of recurrent clots compared to those taking aspirin.
Research links common painkillers diclofenac and ibuprofen to increased risk of cardiac arrest, with diclofenac being the most hazardous. The study advises limiting ibuprofen to 1200mg per day and avoiding diclofenac in patients with cardiovascular disease or high-risk factors.
Researchers at UC Davis Health found that doctors and patients often have differing priorities for pain treatment, with patients seeking to reduce pain intensity and physicians focusing on improving physical function. The study recommends pain-focused communication training to improve doctor-patient agreements.
Researchers propose a $10 billion public-private partnership to fund new research on pain biology and development of non-addictive medications. The plan focuses on understanding individual variability in response to pain, biomarkers for drug efficacy, and complementary approaches such as acupuncture and mindfulness techniques.
Researchers at Charité - Universitätsmedizin Berlin have discovered a new mechanism of action for painkillers that produces substantial pain relief in inflamed tissues without causing severe side effects. The prototype, NFEPP-prototype, binds to opioid receptors only in acidic environments, avoiding respiratory depression and dependency.
A recent study by Georgia State University researchers found that female brains have more active immune cells in pain processing regions. This leads to improved response to opioid pain medication, often less effective in females.
A study analyzing nearly 30,000 liver transplant patients found elevated death and organ loss rates among those with high opioid use while waiting for a transplant. Transplant candidates requiring high levels of opioids should be carefully assessed before and after transplantation.
A new wireless patch has shown significant results in reducing migraine pain, with 64% of participants experiencing a 50% or greater reduction in pain after using the device. The study found that starting stimulation within 20 minutes of a migraine's onset was more effective in reducing pain.
A study found a significant association between increased use of antithrombotic drugs and subdural hematoma incidence in Denmark from 2000 to 2015. The risk was highest for patients taking multiple anticoagulant medications, particularly those combining vitamin K antagonists with antiplatelet drugs.
A novel non-pharmacological approach using green LED has shown promising results in treating neuropathic pain in rats with no side effects observed. The therapy may work by increasing levels of endogenous opioids, which inhibit pain and decrease inflammation.
Researchers found that a subgroup of NSAIDs also act strongly on another family of enzymes called caspases, which play a key role in aggressive immune responses like sepsis. The study suggests that these drugs could be repurposed to address other conditions and develop safer versions.
Scientists at the University of Utah have discovered a compound from the venom of a small Caribbean Sea snail that blocks pain by targeting a distinct pathway not associated with opioid drugs. The benefits of the compound continue even after it has cleared the body, suggesting a potential new therapy for chronic pain.
A Saint Louis University researcher is using a $363,000 grant to test two molecules as potential biomarkers for four debilitating health conditions: chemotherapy-induced peripheral neuropathy, endometriosis, interstitial cystitis, and vulvodynia. The goal is to develop new painkillers that target these pathways.
The American College of Physicians recommends treating acute and subacute low back pain with non-pharmaceutical therapies like heat, massage, and spinal manipulation. For chronic low back pain, exercise, multidisciplinary rehabilitation, and acupuncture are shown to improve symptoms.
Researchers propose that aspirin's anti-tumor effect is due to its ability to block platelet interaction with cancer cells. The study suggests that aspirin can curb tumor growth by reducing circulating platelets and their activity.
A new study suggests that widely used pain relievers may increase the risk of a heart attack when used during a cold or flu-like illness. Researchers found a stronger association with a heart attack when both an acute respiratory infection and NSAID use were present, with a 3.4-fold increased risk for a heart attack.
New research from The George Institute for Global Health reveals that commonly used non-steroidal anti-inflammatory drugs provide limited short-term pain relief and cause significant side effects. The study highlights the need for developing new therapies to treat back pain, which affects 80% of Australians during their lifetime.